# US 10,869,850 B2 · Nitrated-fatty acids modulation of type II diabetes

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 10,869,850 B2
- Document ID: US10869850B2
- Status: Granted
- Kind: B2
- Application number: 16/748,453
- Filed: 2020-01-21
- Published: 2020-07-23
- Granted: 2020-12-22
- Earliest claimed: 2007-08-01
- Assignees: University of Pittsburgh—Of the Commonwealth System of Higher Education
- Applicants: University of Pittsburgh—Of the Commonwealth System of Higher Education
- Inventors: Bruce A. Freeman; Francisco J. Schopfer
- Web page: https://patentgrep.com/patent/US10869850B2

## CPC

- A61K 31/201: having one or two double bonds, e.g. oleic, linoleic acids
- A61K 31/20: having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Nitro oleic acid and related metabolites are agonists of PPAR-γ. Surprisingly, nitro oleic acid is a more potent agonist of PPAR-γ, relative to nitro linoleic acid. Thus, nitro oleic acid and its metabolites, as well as their pharmaceutically acceptable salts and prodrug forms, are candidate therapeutics for the treatment of type-2 diabetes, which results from insulin resistance accompanying the improper functioning of PPAR-γ.

## Claims

### Claim 1

An oral unit dosage form comprising a pharmaceutical composition, the pharmaceutical composition comprising (A) 10-nitro-octadecenoic acid, or a pharmaceutically acceptable salt or prodrug thereof, and (B) a pharmaceutically acceptable carrier.

### Claim 2

An oral unit dosage form comprising a pharmaceutical composition comprising (A) 9-nitro-octadecenoic acid, or a pharmaceutically acceptably salt or prodrug thereof, and (B) a pharmaceutically acceptable carrier.

### Claim 3 (depends on 1)

The oral unit dosage form of claim 1, wherein 10-nitro-octadecenic acid comprises a single regioisomer.

### Claim 4 (depends on 2)

The oral unit dosage form of claim 2, wherein 9-nitro-octadecenic acid comprises a single regioisomer.